# Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

> **NCT06578520** · PHASE4 · RECRUITING · sponsor: **Fundación para la Investigación del Hospital Clínico de Valencia** · enrollment: 31 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT06578520
- **Lead sponsor:** Fundación para la Investigación del Hospital Clínico de Valencia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-30
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06578520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06578520, "Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06578520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*